Fox Susan H, Brotchie Jonathan M, Lang Anthony E
Movement Disorders Clinic, Division of Neurology, University of Toronto, Toronto, ON, Canada.
Lancet Neurol. 2008 Oct;7(10):927-38. doi: 10.1016/S1474-4422(08)70214-X.
Non-dopaminergic treatments are increasingly being recognised as part of the therapeutic armamentarium for Parkinson's disease (PD). Clinical and pathological studies have shown that the disease extends beyond the substantia nigra pars compacta and involves various non-dopaminergic neurotransmitter systems that mediate both motor and non-motor symptoms that characterise PD. To date, several therapeutic strategies have been proposed to treat such symptoms. However, despite the significant morbidity associated with these symptoms, particularly non-motor symptoms, research into and drug development for problems such as mood and autonomic dysfunction remain scarce. Here, we review novel non-dopaminergic approaches that are in at least phase II clinical development for the treatment of PD.
非多巴胺能治疗越来越被视为帕金森病（PD）治疗手段的一部分。临床和病理研究表明，该疾病不仅局限于黑质致密部，还涉及各种非多巴胺能神经递质系统，这些系统介导了PD的运动和非运动症状。迄今为止，已经提出了几种治疗这些症状的策略。然而，尽管这些症状，特别是非运动症状会导致严重的发病率，但针对情绪和自主神经功能障碍等问题的研究和药物开发仍然很少。在这里，我们综述了至少处于II期临床开发阶段的用于治疗PD的新型非多巴胺能方法。
